Merck & Co. Inc.'s PD-1 inhibitor Keytruda performed well in the second quarter and has a dominant market position in first-line lung cancer with a 26% market share of new patient starts in the US – more than any other drug in that setting, the company reported July 28.
The company revealed above-consensus pharma sales of $8.8bn in the second quarter, up by 2% from the same period in...